Evidence map›Paper›PMID 26331115›Full record

ArticleCardiovascular diagnosis and therapy2015

A novel management program for hypertension.

Chun-Song Hu, Ya-Ling Han, Jun-Bo Ge, Qing-Hua Wu, Yan-Na Liu, Chang-Sheng Ma, Tengiz Tkebuchava, Da-Yi Hu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular diagnosis and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Novel strategies halt cardiovascular, diabetes, and cancer strips.Chronic diseases and translational medicine · 2017
    Review
  2. Is Time an Important Problem in Management of Hypertension and Hypercholesterolemia by Using an Amlodipine-Atorvastatin Single Pill Combination?Medical science monitor : international medical journal of experimental and clinical research · 2016
    Article
  3. Structure-editing: A New Branch?Chinese medical journal · 2016
    Article
  4. Health: a dream from reality to the future.Frontiers of medicine · 2016
    Article
  5. New "P" in Medical Model.Chinese medical journal · 2016
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chun-Song Hu1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China.
Ya-Ling Han1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China.
Jun-Bo Ge1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China.
Qing-Hua Wu1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China.
Yan-Na Liu1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China.
Chang-Sheng Ma1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China.
Tengiz Tkebuchava1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China.
Da-Yi Hu1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this article, we describe a comprehensive management program for hypertension (HTN), based on the experience of leading cardiovascular centers in China. This comprehensive approach, adhering to a number of core principles, includes diagnosis and therapeutic interventions. Therapeutic management includes lifestyle changes, risk factor management and pharmacological intervention and should allow reliable lowering blood pressure (BP). Additional paragraphs discuss the relationship between paroxysmal atrial fibrillation (PAF), and HTN.

Indexed as

Hypertension (HTN)paroxysmal atrial fibrillation (PAF)treatment

Identifiers

PMID26331115
PMCPMC4536474

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.